83950 Oncoprotein her-2/neu
Also known as: HER2/neu test, HER2 assay
Quantitative measurement of human epidermal growth factor receptor 2 (HER2/neu) oncoprotein in tissue or blood using immunoassay.
In Plain Language
breast cancer marker; tumor growth protein
Clinical Context
Prognostic and predictive test for breast cancer determining eligibility for anti-HER2 therapy (trastuzumab). Approximately 20-25% of breast cancers are HER2-positive.
RVU Information
CPT 83950 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Lab and pathology codes require an order from the treating provider with clinical indication. For molecular pathology and genetic testing, document the specific analytes tested and clinical rationale.
How This Code Compares
This code has a work RVU of 0.00, meaning it does not have a physician work component assigned by CMS. In the Pathology & Lab category, 94% of codes share this characteristic.
Specialties
Frequently Asked Questions
What is CPT code 83950?
CPT 83950 (Oncoprotein her-2/neu) is a Pathology & Lab code. Quantitative measurement of human epidermal growth factor receptor 2 (HER2/neu) oncoprotein in tissue or blood using immunoassay.
Who uses CPT code 83950?
CPT 83950 is used by Pathology, Oncology, Breast Surgery. Prognostic and predictive test for breast cancer determining eligibility for anti-HER2 therapy (trastuzumab). Approximately 20-25% of breast cancers are HER2-positive.
When is CPT 83950 used?
Prognostic and predictive test for breast cancer determining eligibility for anti-HER2 therapy (trastuzumab). Approximately 20-25% of breast cancers are HER2-positive.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.